Go to Main Content

 

 

HELP | EXIT

Common Course Numbering System

 

Your current Institution is CCCS
Transparent Image

 Searching Current Courses For Fall 2016

  Course: PAP 224
  Title:Pharmacology I
  Long Title:Pharmacology I
  Course Description:Introduces the study of therapeutic pharmacology with emphasis on pharmokinetics and pharmodynamics. The physiology that underlies drug contraindications, interactions and adverse effects is reviewed.
  Min Credit:1
  Max Credit:

  Course Notes: Previously PAP 230; made revisions 7/28/09 s@
  Origin Notes: RRCC
  Status Notes: corresponds to 37.5 contact hours
   S: For the Physician Assistant Program, 1 hour credit

 I. Describe the concepts of clearance, volume of distribution, half-life, bioavailability and therapeutic equivalence.
 II.       When given the half-life of a drug, determine how long it takes to achieve steady-state concentration of the drug.
 III.       List the four major mechanisms for drug interactions and describe the usual time course of these interactions.
 IV.       When presented with a patient with potential drug interaction, develop an appropriate management plan.
 V.       Describe changes in adsorption, distribution, metabolism and excretion found in infants and neonates.
 VI.       Describe changes in adsorption, distribution, metabolism and excretion found in geriatric patients.
 VII.       Describe the relationship between the stages of fetal development and drug effects.
 VIII.       List and describe the FDA categories of teratogenic risk of drugs.
 IX.       Cite examples of drugs, which may exacerbate congestive heart failure.
 X.       Evaluate the effect of compensatory effects of cardiac dilation and hypertrophy.
 XI.       Evaluate the effect of compensatory mechanisms of renal and autonomic origin.
 XII.       Describe the mechanism of action of diuretic therapy.
 XIII.       When given patient specific parameters, be able to recommend an appropriate diuretic for the treatment of congestive heart failure and explain rationale for choice.
 XIV.       Describe the adverse effects associated with diuretic agents in the treatment of congestive heart failure.
 XV.       Discuss the proposed pharmacological mechanism of action of cardiac glycosides.
 XVI.       Discuss the risk versus benefit controversy over the use of digoxin in congestive heart failure.
 XVII.       Describe the signs and symptoms of digitalis toxicity and factors which contribute to the development of digitalis toxicity.
 XVIII.       Describe the effect and significance of selected drug interactions with digoxin.
 XIX.       Identify the level of elevated cholesterol which requires treatment and the factors that influence the level at which treatment is indicated.
 XX.       Discuss the issues of low HDL levels and high triglyceride levels and define whether or not you should treat either.
 XXI.       Describe the mechanism of action for various lipid-lowering drugs.
 XXII.       Describe the side effects, proper monitoring, and contraindications of the various lipid-lowering drugs.
 XXIII.       Describe how the various lipid-lowering drugs should be dosed, and how to minimize side effects and increase compliance with these drugs.
 XXIV.       Describe the appropriate goals for lipid lowering therapy.
 XXV.       Describe the appropriate use and give an example of a wet dressing, bath, powder, lotion, cream and ointment.
 XXVI.       Describe the appropriate use of various potencies of topical corticosteroids.
 XXVII.       Describe the general principals of use for topical corticosteroids and when presented with a case scenario, apply the general principals to a specific patient.
 XXVIII.       List the side effects of topical corticosteroids and tell whether the side effect is reversible or not.


 I.   1.Intro to Pharmacology
 A.        Receptor Sites of Action
 B.        Concentration ¿ Response
 II.       Intro to Pharmacokinetics
 A.        Absorption
 B.        Distribution
 C.        Metabolism
 D.        Elimination
 E.        Theraputic
 F.        Index
 G.        Routes of Admin.
 H.        Dosing Parameters
 I.        T ½
 J.        Steady State
 III.       Drug Interactions
 A.        Inducers
 B.        Inhibitors
 C.        Drug Monitoring
 D.        Acetylation
 IV.       Cardiovascular
 A.        Hyperytension
 B.        Arrhythmias
 C.        Angina
 D.        Hyperlipidomia
 E.        Diuretics
 F.        B-blockers
 G.        Ace Inhibitors
 H.        Calcium Channel Blockers
 I.        Agonists
 J.        Cardiac Glucosides
 K.        Anticogluation
 L.        Nitrates
 M.        Antiarrhythmics
 V.       Pediatrics/Geriatrics
 A.        Dosage Adjustments
 B.        Fever
 C.        Otitis Media
 D.        Conjuctivitis
 E.        Poisoning
 VI.       Dermatology
 A.        Warts
 B.        Herpes
 C.        Candida
 D.        Scabies
 E.        Acne
 F.        Psoriasis
 G.        Eczema
 H.        Urticaria
 I.        Burns
 J.        Wounds
 K.        Dry Skin
 L.        Anesthetics
 M.        Sunscreens
 N.        Insect Repellents
 O.        Antifungals
 P.        Antibacterials
 Q.        Epithedial
 R.        Stimulants
 S.        Keratolyties
 T.        Pediculocides
 U.        Corticosteroids



 Course Offered At:

  Red Rocks Community College RRCC
Transparent Image
Skip to top of page

Skip CCNS Pub Presentation Links

[ CCNS Main Menu ]

Release: 8.5.3